Protagonist Therapeutics Inc PTGX

$132.62 -1.76 (-1.31%)

Valuation

Market cap
8,802,311,000
Revenue TTM
$46,020,000
Net income TTM
$-130,150,000
P/E (trailing)
28.87
P/E (forward)
24.68
Profit margin
-282.81%
Debt to equity
0.00

Trading

Volume
185,120
Avg volume
705,230
Day's range
$131.37 – $134.90
Shares out
65,270,000
Stochastic %K
35%
Beta
1.21
Analysts
Strong Buy
Price target
$180.19

Price

Company profile

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development f...

Show more

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Industry
Biotechnology
Sector
Healthcare
Phone
510 474 0170
Website
https://www.protagonist-inc.com
Address
7707 Gateway Boulevard, Suite 140, Newark, United States

Latest news

Stocktwits

Merlintrader Nov 11, 1:54 AM
$PTGX Protagonist (PTGX): net income $220.0M, MIMRYLO approved by FDA Free weekly catalyst newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13 Not investment advice.
0 replies
WallStWireAds Nov 9, 9:58 PM
$PTN Palatin’s Peptide Is Advancing Toward the Clinic as Big Pharma Pays Billions for Early Peptides >> https://www.benzinga.com/content/63030955/palatin-s-peptide-advancing-toward-clinic-big-pharma-pays-billions-early-peptides-nasdaq-ptn Gilead's $1.275 billion upfront commitment for a peptide still in Phase 1 is the latest sign that drugmakers are willing to pay for a better-designed molecule early in clinical development. Palatin Technologies (NASDAQ:PTN) is preparing its own next-generation peptide for first human testing in 2027. $GILD $RYTM $PTGX
0 replies
Quantumup Nov 9, 12:33 PM
Wedbush reiterated $PTGX Outperform-$173 after the Co reported +VE data from its Ph1 SAD study of the subQ formulation of PN-477, a GLP-1/GIP/GCG triple agonist peptide for obesity—3Q26 earning. [TAK IONS IRON AGIO SLN [JNJ ABBV ABVX BMY [LLY NVO VKTX GPCR MBX KLRA]]] Wedbush said in its note: https://x.com/Quantumup1/status/2119770055558709635?a=bi7r8OuwzQtr2gxiLa0&s=20
0 replies
Ian_FV Nov 6, 2:25 AM
6-K/8-K Important Update $PTGX Protagonist Therapeutics, Inc. received FDA approval for MIMRYLO, its therapy for polycythemia vera, resulting in $275 million in payments from Takeda. The company also announced approval for ICOTYDE, an oral IL-23 receptor antagonist for psoriasis, in China, Japan, and the EU, with royalties ranging from 6% to 10% on global sales. Additionally, Protagonist initiated a $300 million share repurchase program, supported by cash, marketable securities, and royalties, with $834.6 million in cash and equivalents as of September 30, 2026. More details at www.ianfv.com
0 replies
Mikedawgs Nov 5, 9:11 PM
$PTGX how’s everyone feeling about earnings
0 replies
AXLFI_HQ Nov 5, 12:42 AM
The most recent Momentum signal on $PTGX triggered on 2026-11-04. The expected return for the selected horizon is +37.49% with a historical profit probability of +72.22%. Learn more: https://axlfi.com/factors/stock/PTGX/momentum/daily?pass=eyJrIjoibGluayIsImUiOjE3OTQwMTIxNjF9.izpyDWLmgrAR9fNrGFcc-w
0 replies
Merlintrader Oct 27, 8:46 PM
$PTGX — Four November bank conferences. Information only — not investment advice. More details in our hub.
0 replies
Merlintrader Oct 21, 11:36 PM
$PTGX Latest analyst update, Oct 21, 2026: TD Cowen kept Buy and raised its price target on Protagonist Therapeutics to 160 USD from 155 USD. Third-party analyst opinion. More details in our $PTGX stock hub. Not investment advice.
0 replies